Tests dried chicory root fiber in people with melanoma skin cancer
Tests daily chicory root fiber for 6 weeks in adults after melanoma surgery.
Plain-language title generated from the registry record
Registry title: Explorative Study on Addition of High-fiber Dried Chicory Root in Patients With an Intermediate to High-risk Cutaneous Melanoma.
Key facts
- Where
- Groningen, NetherlandsSee the site
Where in Netherlands
- UMCGGroningen, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Medical Center Groningen
- Trial code
- NCT07206017
- Record updated
- 3 October 2025
- Original description
Exploring the effect of supplementation with daily addition of prebiotic dried chicory root (WholeFiberTM) for 6 weeks on fecal SCFA levels, gut microbial composition and immune cell composition in minimal stage II A melanoma patients following surgical treatment.Read full original descriptionShow less
Measuring Effects of High-fiber Dried Chicory Root on the Gut Microbiota of Patients With an Intermediate to High-risk Cutaneous Melanoma: an Explorative Study
Exploring the effect of supplementation with daily addition of prebiotic dried chicory root (WholeFiberTM) for 6 weeks on fecal SCFA levels, gut microbial composition and immune cell composition in minimal stage II A melanoma patients following surgical treatment.
Inclusion: Age ≥18 years; The participant understands the study and can provide written informed consent; The participant received surgical treatment of an intermediate to high-risk cutaneous melanoma (T2a/N1, T2b, T3a, T3b, T4a, T4b, N0 or N+, M0 stadium without evidence of disease); Being able to read and speak Dutch; Willing to come to the UMCG for practical reasons (visiting the study site); Willing to continue their regular lifestyle patterns during the study.
Exclusion: Receiving concurrent adjuvant treatment, adjuvant treatment after the study period is allowed; Use of antibiotics in the 3 months prior participation in the study; Use of prednisolone or other immunosuppressive medication; Having a medical history that may impact study outcomes, such as a diagnosis of diabetes mellitus type 2, heart disease, renal disease, autoimmune disease; Any clinically significant or unstable medical disorder involving the gut, including celiac disease, inflammatory bowel disease, short-bowel syndrome or acute/chronic pancreatitis; Having an ileostomy or colostomy, as this greatly impacts bowel function and gut microbial composition; Use of tube feeding or sib-feeding; Being pregnant or lactating; Participation in another interventional study at the same time; Unable or unwilling to comply to study rules.